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Abstract
Modified gangliosides may be overexpressed in certain types of cancer, thus, they are considered a valuable target in cancer
immunotherapy. Structural knowledge of their interaction with antibodies is currently limited, due to the large size and high
flexibility of these ligands. In this study, we apply our previously developed site mapping technique to investigate the
recognition of cancer-related gangliosides by anti-ganglioside antibodies. The results reveal a potential ganglioside-binding
motif in the four antibodies studied, suggesting the possibility of structural convergence in the anti-ganglioside immune
response. The structural basis of the recognition of ganglioside-mimetic peptides is also investigated using site mapping
and compared to ganglioside recognition. The peptides are shown to act as structural mimics of gangliosides by interacting
with many of the same binding site residues as the cognate carbohydrate epitopes. These studies provide important clues
as to the structural basis of immunological mimicry of carbohydrates.
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Introduction
Gangliosides are glycosphingolipids which feature one or more
sialic acid residues. They are most often associated with nervous
system function, where they play a crucial role in maintaining the
stability of myelin and axons [1]. Alterations in ganglioside
expression levels have been associated with several neurodegen-
erative conditions, including Alzheimer’s disease, Parkinson’s
disease, Huntington’s disease and HIV-associated dementia [2].
The production of anti-ganglioside antibodies is one of the key
biochemical features of Guillain-Barre ´ syndrome, an autoimmune
neuropathy [3]. While the specific cause of the syndrome is
unknown in the majority of cases, it is commonly preceded by
infection with Campylobacter jejuni [4,5].
Gangliosides have been identified as tumor-associated carbo-
hydrate antigens (TACAs), a group which includes Lewis Y, Lewis
X, Thomsen-Friedenreich and Thomsen-nouvelle [6]. The
gangliosides most often found in the nervous system are GM1,
GD1a, GD1b and GT1b [1], however, the gangliosides considered
for vaccine and antibody-based targeting are generally biosyn-
thetic intermediates of these, such as GM2, GM3, GD2 and GD3
[7,8,9,10] (Figure 1). While found in low amounts in the nervous
system, they often appear in high densities on a variety of tumor
cell types [11,12,13]; thus, they are attractive targets for cancer
immunotherapy. In addition to these, gangliosides terminating in
N-glycolylneuraminic acid (Neu5Gc), such as N-glycolyl GM3
(Neu5Gc-GM3), are also useful targets for cancer treatment
[14,15]. Unlike N-acetylneuraminic acid, Neu5Gc cannot be
synthesized by humans, due to the lack of a functional sialic acid
hydroxylase [16]. The appearance of Neu5Gc on human cells is
thought to come about through enzymatic incorporation from diet
[17]. Since Neu5Gc expression is largely restricted to cancer cells
in humans, targeting Neu5Gc-terminating gangliosides is likely to
achieve a highly selective therapeutic outcome.
Carbohydrates are normally considered T cell-independent
antigens, typically incapable of inducing a strong immune
response [18,19]. One way to address this issue is through the
development of carbohydrate mimetics, capable of inducing an
anti-carbohydrate immune response. Peptides have been consid-
ered for this purpose against a wide range of targets [20]. Peptide
mimics of the GD2 [21,22,23] and GD3 [24,25] gangliosides have
been identified, typically by phage display against anti-ganglioside
antibodies. Some of these have been found to induce anti-
ganglioside immune responses [23,25,26]. Peptide mimics of anti-
Neu5Gc-GM3 antibodies are not currently known, however, anti-
idiotypic antibodies against these antibodies have been identified
[27,28].
Although prior structural studies into the recognition of
gangliosides and their mimics by antibodies have been performed
[21,29,30,31], these have generally utilized simple molecular
docking methodologies. We have previously developed the site
mapping technique, which we have demonstrated to be effective
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lectin recognition [34], as well as peptide-antibody recognition
[35,36,37,38]. Here, we evaluate a range of molecular docking
programs for their ability to predict the binding modes of acidic
sugars to antibodies and apply our site mapping technique to study
antibody recognition of acidic sugars (Table 1). The computational
approach most suitable for the validation cases is then utilized to
investigate recognition of carbohydrate epitopes of gangliosides by
four anti-ganglioside antibodies: R24, ME36.1, chP3 and 14F7
(Table 2). While there are experimentally solved native structures
of all of the antibodies of interest available, the structure of one of
these antibodies, chP3, is missing a short segment of the key
HCDR3 loop. We have thus extended the site mapping technique
to consider multiple protein conformers, in a process termed
‘‘dynamic site mapping’’. Finally, the site mapping technique is
used to investigate antibody recognition of ganglioside-mimetic
peptides, which is compared to recognition of the carbohydrate
determinants of gangliosides.
Methods
Validation and test systems
For method validation, high resolution complexes (,2.5 A ˚)o f
the antichlamydial antibodies S25-2, S73-2 and S25-39 with poly-
Kdo (ketodeoxyoctulosonic acid) antigens were obtained from the
Protein Data Bank (PDB) (Table 1). The test systems examined
(anti-ganglioside antibodies and their ligands) are summarized in
Table 2. Antibodies were numbered and CDRs defined following
the IMGT unique numbering scheme [39].
Molecular docking
Glide 5.6 [40,41], GOLD 4.1.1 [42], AutoDock 4.2 [43] and
DOCK 6.4 [44] were evaluated for their ability to reproduce the
crystallographic binding mode in each of the validation systems.
The settings used for these programs are detailed elsewhere
[34,45]. Briefly, the ligands were treated flexibly by each docking
program, with the exception of the pyranose rings, which were
kept in chair conformations. In the validation cases, all
crystallographic waters and buffer molecules, as well as ions, were
removed from the structures. The Protein Preparation Wizard in
Maestro 9.2 [46] was used to add hydrogens and determine the
most likely protonation states of titratable protein residues in all
cases.
Site mapping
The site mapping procedure was applied to the test systems as
described previously [32]. Briefly, the interactions taking place in
the top 100 ranked poses obtained from molecular docking are
tallied according to the protein residue with which they occurred
and the type of interaction taking place (i.e., hydrogen bond or van
der Waals interaction). The tallies are normalized by dividing the
number of interactions observed with a particular residue by the
total number of interactions observed. Normalization is performed
separately for hydrogen bonding and van der Waals interactions.
Figure 1. Carbohydrate determinants of gangliosides com-
monly found in the central nervous system and cancer cells.
CNS gangliosides: A. GT1b. B. GD1a. C. GD1b. D. GM1. Cancer-related
gangliosides: E. GD2. F. GD3. G. GM3. H. Neu5Gc-GM3. Since each
structure is differentiated by the removal of one or more residues from
GT1b, the glycosidic linkages specified on GT1b apply to all of the
structures, including Neu5Gc-GM3. Carbohydrate symbols follow the
nomenclature of the Consortium for Functional Glycomics [63]: N-
acetylneuraminic acid – purple diamond; galactose – yellow circle; N-
acetylgalactosamine – yellow square; glucose – blue circle; N-
glycolylneuraminic acid – light blue diamond.
doi:10.1371/journal.pone.0035457.g001
Table 1. Validation systems.
PDB ID Carbohydrate Antibody Resolution Reference
1Q9Q Kdoa(2R8)Kdoa(2R4)Kdoa(2-OAll) S25-2 1.49 [50]
1Q9T Kdoa(2R8)Kdoa(2-OAll) S25-2 1.74 [50]
3HZK Kdoa(2R4)Kdoa(2-OAll) S73-2 2.15 [51]
3HZV Kdoa(2R8)Kdoa(2R4)Kdoa(2-OAll) S73-2 1.90 [51]
3HZY Kdoa(2R4)Kdoa(2R4)Kdoa(2-OAll) S73-2 2.10 [51]
3OKK Kdoa(2R4)Kdoa(2-OAll) S25-39 1.95 [52]
3OKL Kdoa(2R8)Kdoa(2-OAll) S25-39 1.80 [52]
3OKN Kdoa(2R4)Kdoa(2R4)Kdoa(2-OAll) S25-39 2.15 [52]
3OKO Kdoa(2R8)Kdoa(2R4)Kdoa(2-OAll) S25-39 2.45 [52]
doi:10.1371/journal.pone.0035457.t001
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contribution, and the cumulative sum is calculated. All residues
which occur above a given cumulative sum cutoff are deemed
important for recognition.
The metrics of reproduction and correctness were used in the
assessment of site map quality. Reproduction is calculated as the
number of crystallographic interactions identified by the site map
divided by the number of crystallographic interactions observed.
Correctness is calculated as the number of crystallographic
interactions identified by the site map divided by the total number
of mapped interactions. Reproduction and correctness values close
to one indicate that the generated site maps accurately identify the
crystallographic interactions, without the inclusion of erroneous
contacts. The product of reproduction and correctness was used to
assess the quality of mapping; larger values indicate optimal
reproduction and correctness. The cumulative sum cutoff was
optimized for the validation systems by assessing the average
product of reproduction and correctness at 10% cutoff intervals
from 0–100%. The cutoff which provided the greatest average
product for the series of validation cases (Table 1) was applied to
investigate the recognition of gangliosides and ganglioside-mimetic
peptides by the selected anti-ganglioside antibodies (Table 2).
Dynamic site mapping
Three residues of the HCDR3 loop are missing from the
structure of chP3 (PDB 3IU4) [30]. The missing portion was
manually built, and low energy conformers of this portion, as well
as the residue adjacent to each side of the missing portion (making
a total of five residues), were generated using the loop refinement
tool in Prime [47]. The site mapping procedure (see above) was
performed on the ten lowest energy conformers. The most likely
conformer from the set was selected on the basis of its similarity to
the ensemble average of the hydrogen bonding and van der Waals
site maps. The ensemble average maps were calculated by
averaging the interaction contributions of each mapped residue
across the set of ten conformers. The similarity of each
conformer’s site maps to the ensemble average was determined
using the following expression:
Similarity~
a|r2
HBzb|r2
vdW
azb
where a is the cutoff for selection of important hydrogen bonding
contacts (as a fraction), b is the cutoff for selection of important van
der Waals contacts (as a fraction), r
2
HB is the correlation coefficient
calculated between a particular conformer and the ensemble
average for hydrogen bonding contacts, and r
2
vdW is the
correlation coefficient calculated between a particular conformer
and the ensemble average for van der Waals contacts. The
conformer exhibiting the highest similarity to the ensemble
average maps was selected as the most likely conformer.
Peptide mimicry of gangliosides
Ganglioside-mimetic peptides were separated into overlapping
hexapeptide fragments and docked to the antibody targets using
GOLD. The site mapping technique (see above) was applied to the
resulting ensembles of poses. The interaction data for the set of
hexapeptides was pooled to give one set of site maps for the
complete peptides, as described earlier [36].
Comparison of ganglioside and mimic recognition
To compare the recognition of gangliosides and their peptide-
based mimics, scatter plots comparing the interaction contribu-
tions of antibody residues in ganglioside recognition and mimic
recognition were generated. The distance between each point and
the line representing equivalence of ganglioside and mimic
recognition (d) was computed as described previously [36]. Positive
d values indicate a greater number of interactions by that residue
with the mimic, while negative d values indicate more interactions
with the ganglioside. Residues with d greater than an absolute
value of 3.00 were considered to vary significantly from the
equivalence line.
Results
Molecular docking evaluation
Several molecular docking programs were evaluated for their
ability to predict the crystallographic binding mode of a series of
antichlamydial antibodies in complex with poly-Kdo antigens
(Table 1). The results of molecular docking evaluation demon-
strate that most programs are generally unsuccessful in accurately
ranking the crystallographic binding mode (Table 3). However, all
of the programs were able to identify the correct binding mode
(i.e., less than 2.0 A ˚ rmsd between pose and crystallographic
binding mode) for at least one case, regardless of ranking. The
exception to this is GOLD, which was able to both accurately
identify and rank, as the top pose, the correct binding mode in four
cases, these being all of the S73-2 complexes (PDB codes 3HZK,
3HZV and 3HZY), and the complex of S25-39 with
Kdoa(2R4)Kdoa(2-OAll) (PDB 3OKK). Two of these successful
cases are shown in Figure 2. In general, increasing the size and
flexibility of the carbohydrate determinant being examined led to
reduced quality predictions. Furthermore, the binding site
topography may also impact on the quality of predictions, as
observed previously [45], however, too few appropriate model
complexes are available to confirm this.
Optimization of site mapping for antibody recognition of
acidic sugars
Since GOLD produced the most accurate poses, irrespective of
the ability to rank those poses, it was used to provide the pose
ensemble input for site mapping. A cumulative sum cutoff of 80%
for both hydrogen bonding and van der Waals interactions has
Table 2. Test systems.
PDB ID Antibody Carbohydrate Mimic
a Resolution (A ˚) Reference
1BZ7 R24 GD3 RHAYRSMAEWGFLYS 2.50 [66]
1PSK ME36.1 GD2 LDVVLAWRDGLSGAS 2.80 [67]
1RIH 14F7 Neu5Gc-GM3 mAb 4G9 2.50 [29]
3IU4 chP3 Neu5Gc-GM3 mAb 1E10 1.75 [30]
aOnly peptide-based inhibitors are examined in the current study. Anti-idiotypic antibodies are included for reference.
doi:10.1371/journal.pone.0035457.t002
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antibodies, where shorter, less flexible and less functionally diverse
carbohydrates were considered [32]. This cutoff has also been
successfully applied to peptide-recognizing antibodies and carbo-
hydrate-lectin interactions [34,36]. In order to determine whether
this cutoff was appropriate for studying antibody recognition of
acidic sugars with highly flexible linkages (i.e., (1R6) or (2R8)
linkages), a range of cutoff values was investigated (Table S1). The
90% cutoff was found to be most consistent, affording a lower
standard deviation in the product data (i.e., reproduction6correct-
ness) obtained for the set of cases (S.D.=0.05). The 80% cutoff
afforded an identical mean to the 90% cutoff across the set of
studied cases, but was slightly less consistent than the 90% cutoff
(S.D.=0.08). However, the use of the 90% cutoff resulted in
relatively poor map correctness (,0.5–0.6) compared to previous
cases [32,34,36]. This low level of map correctness can be
attributed to the inclusion of many erroneous van der Waals
contacts.
In order to optimize the selection of interacting residues,
hydrogen bonds and van der Waals contacts were considered with
separate cutoffs, instead of the same cutoff for each interaction
type as previously used [32,34,36]. When hydrogen bonding was
considered alone, the 90% cutoff was found to be optimal for the
range of test systems (Table S2) and gave superior results to
considering both hydrogen bonding and van der Waals with the
same cutoff. Consideration of some van der Waals contacts is
needed to identify interactions with non-polar sidechains. It was
found that a 40% cutoff for van der Waals contacts, in
combination with a 90% cutoff for hydrogen bonding interactions,
provided the optimal prediction of crystallographic contacts (Table
S3).
Using this optimized cutoff, it was demonstrated that site
mapping and the top pose obtained from molecular docking
performed comparably at the prediction of interacting residues
(Figure 3, Table 4). Furthermore, this optimized cutoff affords site
map quality comparable in reproduction and correctness to
previously studied antibody- and lectin-carbohydrate systems
[32,34].
Dynamic site mapping of chP3
The structure of chP3 (PDB 31U4) is missing three residues
from the HCDR3 loop [30]. It is known that residues from this
loop are important for antigen recognition by chP3. In order to
identify the most appropriate conformation of this loop,
‘‘dynamic’’ site mapping of chP3, whereby site mapping of
multiple chP3 conformers – varying only in the conformation of
the missing portion of the HCDR3 loop – was carried out. Since
less than ten poses were obtained when docking Neu5Gc-GM3 to
the fourth-lowest energy conformer of the chP3 HCDR3, site
mapping could not be carried out on this structure. The eleventh-
lowest energy conformer was used instead, to make a set of ten
structures.
From site-directed mutagenesis studies, it is known that
Arg111.2H (Arg100AH in Kabat numbering) is critical for
ganglioside recognition [30]. It would therefore be expected that
this residue is heavily involved in antigen interactions. When the
site mapping procedure was carried out on the lowest energy chP3
HCDR3 conformer, Arg111.2H accounted for only 5.31% of all
observed hydrogen bonds, while other residues accounted for a
significantly greater number of hydrogen bonds (Table S4). Thus,
the top scoring conformer is potentially not the most representa-
tive of the biologically relevant state. Similar site maps to this were
observed for the fifth- and ninth-lowest energy chP3 structures.
The second-lowest energy chP3 HCDR3 conformer featured
almost no interactions with Arg111.2H (0.90% of hydrogen bonds
and 1.34% of van der Waals interactions), suggesting that the loop
is also likely to be in a biologically irrelevant conformation. Upon
inspection of this structure, the side-chain of Arg111.2H stacks
with the side-chain of Trp57H, and thus cannot easily interact
with the ligand (Figure 4). In the third-lowest energy structure, the
most hydrogen bonds were observed with Arg111.2H – just over
20% of all hydrogen bonds. Therefore, this structure is likely to be
representative of the biologically relevant state. Other key contacts
in this structure included Ala112.1H, His107L and Tyr108L. The
sixth-lowest energy structure featured Arg111.2H and Ala112.1H
as key contacts, but does not prominently feature the two residues
from the light chain, identified as important for interactions in the
third-lowest energy structure. Instead, Ser38H was identified as a
Table 3. Molecular docking of validation systems.
rmsd values (A ˚)
Glide GOLD Autodock DOCK
PDB code top
a best
b top best top best top best
1Q9Q 6.5 3.7 (15) 6.8 4.3 (2) 6.3 3.7 (27) 9.8 5.7 (7)
1Q9T 4.8 1.5 (7) 3.4 1.0 (5) 7.3 1.9 (3) 5.0 2.0 (4)
3HZK 4.9 1.3 (12) 1.6 1.5 (7) 3.5 3.4 (10) 4.6 1.3 (11)
3HZV 5.0 3.0 (4) 1.1 1.1 (1) 6.6 3.1 (81) -
c -
c
3HZY 8.4 1.2 (11) 1.5 1.2 (4) 8.6 3.2 (48) 8.1 6.3 (3)
3OKK 6.6 1.0 (11) 1.2 1.2 (1) 1.9 1.9 (1) 5.5 3.6 (11)
3OKL 5.8 3.3 (15) 6.6 0.8 (2) 3.6 1.5 (2) 5.5 4.6 (6)
3OKN 8.2 1.7 (11) 3.0 1.3 (8) 7.5 4.1 (30) 6.4 6.4 (1)
3OKO 7.1 2.1 (62) 6.2 3.5 (58) 4.5 3.8 (46) -
c -
c
Mean6S.D. 6.461.4 2.161.0 3.562.4 1.861.2 5.562.2 3.060.9 6.461.9 4.362.1
aPose ranked first by molecular docking program.
bPose which gave the best RMSD value compared to the crystallographic binding mode. The docking rank is shown in parentheses.
cNo ligand poses were obtained following the docking procedure.
doi:10.1371/journal.pone.0035457.t003
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with slightly greater emphasis on interactions with His107L and
Tyr108L. In the seventh-lowest energy structure, Arg111.2H
dominated the hydrogen bonding interactions, accounting for
almost one third of all hydrogen bonds observed with that
structure. However, Ala112.1H, Gln112H, His107L and Tyr108L
each accounted for ,10% of all hydrogen bonds. The tenth- and
eleventh-lowest energy structures afforded similar site maps to one
another, with hydrogen bonds fairly evenly distributed between
Arg112.2H, Ala112.1H, Gln112H, Ala113H, His107L and
Tyr108L.
In all cases, van der Waals contacts were dominated by Trp57H
and Trp116L (Table S5). The HCDR3 residues – Arg111.2H,
Ala112.1H and Gln112H – were also important for van der Waals
contacts. Their importance is usually in line with their importance
for hydrogen bonding (i.e., residues that are strongly important for
hydrogen bonding are typically strongly important for van der
Waals contacts).
In analyzing the generated site maps, it was determined that the
chP3 conformer most representative of the average state was the
tenth-ranked conformer (Figure 4, Table 5). This conformer
features significant hydrogen bonding with Arg111.2H, known to
be important for recognition from site-directed mutagenesis
studies, but also suggests the importance of nearby HCDR3
residues (Ala112.1H, Gln112H, Ala113H) and the LCDR3
residues His107L and Tyr108L. The van der Waals interactions
largely occur with tryptophan residues at positions 57H and 116L.
This residue utilization is similar to other anti-carbohydrate
antibodies [32].
Determination of the likely ganglioside-recognizing motif
We had investigated ganglioside recognition by the four anti-
ganglioside antibodies (Table 2) using identical hydrogen bonding
and van der Waals cutoffs, as per our previous work [20,32,34],
and this identified some of the residues likely to be involved in
ganglioside recognition [48]. To confirm the results of this
preliminary study, these cases have now been re-examined using
the optimized cutoff values. The corresponding carbohydrate
epitopes of the gangliosides were docked to R24, ME36.1 and
14F7, and the optimized cutoffs were applied to identify likely
Figure 2. Evaluation of molecular docking using high resolution crystal structure complexes. A. Comparison of top ranked pose
obtained from molecular docking (yellow) with the crystallographic binding mode (blue) of the Kdoa(2R4)Kdoa(2-OAll):S25-39 complex (PDB 3OKK).
B. Comparison of top ranked pose (yellow) obtained from molecular docking with the crystallographic binding mode (blue) of the
Kdoa(2R8)Kdoa(2R4)Kdoa(2-OAll):S73-2 complex (PDB 3HZV). C. Schematic representation of interactions in the Kdoa(2R4)Kdoa(2-OAll):S25-39
predicted by molecular docking. D. Schematic representation of interactions in the Kdoa(2R8)Kdoa(2R4)Kdoa(2-OAll):S73-2 complex. Molecular
docking carried out using GOLD 4.1.1. Figures 2A and 2B prepared using PyMOL [64]. Figures 2C and 2D prepared using LIGPLOT [65]. Legend to
Figures 2C and 2D: hydrogen bonds – green dashes; hydrophobic interactions – red arcs; carbon – black; oxygen – red; nitrogen – blue; ligand bonds
– purple; protein bonds – orange.
doi:10.1371/journal.pone.0035457.g002
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generated site maps, as well as that generated by the dynamic
mapping procedure applied to chP3, were used to identify the
presence of a potential ganglioside-binding motif in the anti-
ganglioside antibodies. The key residues involved in ganglioside
recognition are summarized in Table 6.
Ganglioside recognition by the antibodies was generally
dominated by interactions with the heavy chain (Figures 4 and
5). In the cases of mAbs R24 and 14F7, recognition was entirely
dependent on heavy chain residues, while for mAbs ME36.1 and
chP3, approximately one third of all interactions occurred with
light chain residues. These differences in CDR utilization can be
explained in terms of the binding site topographies of each of the
antibodies; the binding cavities of R24 and 14F7 are both
comprised entirely of heavy chain residues, with access to the
LCDRs blocked by HCDR2.
Despite the differences in binding site topographies, there are
key similarities between the antibodies which become apparent
upon structural examination of the site maps. Four residues,
arranged in a relatively similar ‘‘spiral’’ around each antibody
binding site, are largely responsible for hydrogen bonding
interactions with the gangliosides. Proceeding clockwise, the likely
ganglioside-binding motif of the antiganglioside antibodies com-
prises two polar residues (typically Ser, followed by Tyr, Thr or
Asp), an aromatic residue (typically Tyr) and a basic residue (Arg).
Not all of the antibodies strictly conform to this motif; for example,
R24 features a threonine residue where an arginine would be
expected, and chP3 features an alanine residue where a serine
would be expected.
Peptide mimicry of gangliosides
The peptide mimic of GD3 – RHAYRSMAEWGFLYS – could
replicate almost all of the van der Waals interactions made by the
ganglioside with R24, but some marked differences in the
hydrogen bonding profile occurred (Table S6). The maps revealed
Table 4. Comparison of predictive ability of the optimized
site mapping procedure and molecular docking.
Reproduction
a Correctness
b
PDB code Site map Top pose Site map Top pose
1Q9Q 0.88 0.88 0.64 0.88
1Q9T 1.00 1.00 0.80 0.80
3HZK 1.00 1.00 0.67 0.73
3HZV 1.00 1.00 0.75 0.90
3HZY 0.80 0.50 0.73 0.71
3OKK 0.86 1.00 0.55 0.88
3OKL 0.78 0.78 0.78 0.78
3OKN 1.00 1.00 0.67 0.80
3OKO 1.00 0.89 0.75 0.88
Mean 6 S.D. 0.9260.09 0.8960.17 0.7060.08 0.8260.07
aComputed as the number of interacting residues correctly identified by the
technique divided by the total number of interacting residues in the
crystallographic complex.
bComputed as the number of interacting residues correctly identified by the
technique, divided by the total number of interacting residues identified by the
technique.
doi:10.1371/journal.pone.0035457.t004
Figure 3. Evaluation of site mapping using high resolution crystal structure complexes. Kdoa(2R4)Kdoa(2R4)Kdoa(2-OAll) binding to
S73-2 (PDB 3HZY) described by hydrogen bonding map (A) and van der Waals interaction map (B). Kdoa(2R8)Kdoa(2R4)Kdoa(2-OAll) binding to
S25-39 (PDB 3OKO) described by hydrogen bonding map (C) and van der Waals interaction map (D). The color depth indicates the level of
involvement of a particular residue in ligand recognition; more strongly illuminated residues are more involved in ligand recognition than weakly
illuminated residues. The crystal structure binding mode is shown in each structure in sticks colored by atom type (C, yellow; O, red). Images rendered
using PyMOL [64].
doi:10.1371/journal.pone.0035457.g003
Ligand Recognition by Anti-Ganglioside Antibodies
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35457that the peptide failed to replicate the number of hydrogen bonds
made between the GD3 trisaccharide and the antibody residues
Gly38H and Ser58H. However, a significant increase in hydrogen
bonds with the HCDR3 residues, Tyr113H and Tyr114H, was
observed. The reduced potential of the peptide to deeply and
consistently penetrate the binding site across the pose ensemble
may explain why fewer interactions were observed with Gly38H
and Ser58H. Tyr113H and Tyr114H may afford more interac-
tions with the peptide, since they are more easily accessible. From
comparison of the ganglioside- and peptide-derived site maps
(Figure 6), the peptide appears to be a partial structural mimic of
GD3 [20]. This partial structural mimicry could account for the
observed immunological mimicry of GD3 by this peptide [25].
The peptide mimic of GD2 could more closely mimic
carbohydrate binding to ME36.1 compared to the peptide mimic
of GD3 binding to R24 (Table S7). Similar to carbohydrate and
peptide binding to R24, the van der Waals interactions of the
carbohydrate were very well replicated by the peptide, while some
minor differences in the hydrogen bonding profile were observed.
A significant increase in hydrogen bonds with Asp55H and
Ser108H was observed, accompanied by a slight drop in hydrogen
bonds with Tyr55L and Ser56L. Despite these differences, the
ganglioside- and peptide-derived site maps for ME36.1 are overall
very similar to one another. Since the peptide is known to be an
immunogenic mimic of GD2 [23], this represents a case of
structural mimicry translating into immunological mimicry
(Figure 7) [20].
Discussion
Carbohydrate-protein recognition is particularly challenging for
molecular docking to predict accurately, due to the multitude of
chemically equivalent hydroxyl groups in carbohydrates and their
potential to form many specific interactions, including CH-p
interactions [45,49]. Evaluation of a variety of molecular docking
approaches against suitable test cases is desirable to ensure the
development of an optimal modeling protocol. We have previously
demonstrated that molecular docking can be an effective tool for
studying antibody recognition of structurally simpler carbohy-
drates [45]. However, gangliosides feature diverse chemical
functionality, including carboxylate groups and flexible hydroxyl-
ated chains. Furthermore, GD2 and GD3 contain a(2R8)
linkages, which feature an additional degree of conformational
freedom compared to, for example, (1R3) and (1R4) linkages,
Table 5. Conformer score for lowest energy conformers of
chP3.
Conformer r
2
HB r
2
VdW Similarity
1 0.69 0.70 0.69
2 0.50 0.59 0.53
3 0.89 0.57 0.79
5 0.66 0.55 0.62
6 0.53 0.40 0.49
7 0.70 0.55 0.65
8 0.72 0.58 0.68
9 0.75 0.79 0.76
10 0.95 0.63 0.85
11 0.87 0.69 0.82
doi:10.1371/journal.pone.0035457.t005
Figure 4. Dynamic mapping of chP3. A. The second-lowest energy
conformer, highlighting the stacking between the side-chains of
Arg111.2H and Trp57H. B. The tenth-lowest energy conformer,
predicted to be most likely to be involved in ligand binding. C.
Hydrogen bonding site map for tenth-lowest energy conformer. D. The
van der Waals map for tenth-lowest energy conformer. Residues
contributing to the proposed ganglioside-binding motif are highlighted
on the hydrogen bonding site maps.
doi:10.1371/journal.pone.0035457.g004
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such systems have not been appropriately evaluated with
molecular docking. While high resolution ganglioside-antibody
complexes are not available for use in method evaluation, a series
of high resolution structures of antichlamydial antibodies in
complex with Kdo-containing carbohydrates are available
[50,51,52] (Table 1); these represent the most suitable model
systems for evaluating the likelihood of success in predicting
ganglioside-antibody recognition. Another issue with molecular
docking is the need to consider the potential of multiple ligand
binding modes. Their effect on recognition by proteins may be
important for highly flexible ligands, such as carbohydrates and
peptides [49]. In order to consider the effect of multiple ligand
binding modes on recognition by proteins [53], we developed the
site mapping technique, which we have demonstrated to be
effective for studying carbohydrate-antibody [32] and carbohy-
drate-lectin recognition [34], as well as carbohydrate-peptide
mimicry [36].
In this study, the site mapping methodology is extended to study
the recognition of acidic sugars, particularly gangliosides, by
antibodies. Furthermore, to study ganglioside recognition by chP3,
a ‘‘dynamic’’ version of the site mapping technique was developed,
whereby multiple antibody conformers are considered to select
one with the most likely ligand-binding conformation. Ganglioside
mimicry is investigated by comparing the site maps describing the
recognition of gangliosides and their peptide-based mimics.
All of the antibodies examined in the validation set (Table 1)
prominently feature arginine residues in their binding sites, which
pair with the carboxylate groups of the complexed carbohydrate.
Since these charge-assisted hydrogen bonds are likely to be highly
energetically favorable, it was anticipated that the pairing effect
would lead to good quality predictions of antibody recognition of
Table 6. Ganglioside recognition by test systems.
a
R24 ME36.1 14F7 chP3
b
Region Position Residue %HB %VdW Residue %HB %VdW Residue %HB %VdW Residue %HB %VdW
HCDR1 35 Thr 5.42 1.31
36 Asn 2.60 2.87 Ser 14.19 16.34
37 Tyr 0.22 3.69 Tyr 4.01 14.71
38 Gly 7.99 3.98 Thr 13.90 7.78 Trp 10.46 10.78
40 His 4.71 3.96 His 3.69 3.42
HCDR2 55
c Tyr 10.39 3.98 Asp 4.60 5.67 Met 3.69 6.05
57 Ser 1.60 5.10 Asn 1.01 2.64 Asp 15.50 8.66 Trp 0.78 14.87
58 Ser 18.28 3.18
62 Thr 4.67 3.10
64 Ser 4.90 4.30
66
c Asn 2.80 0.48 Asn 4.48 1.72 Asp 2.46 1.05
HCDR3 107 Gly 0.10 11.15 Lys 2.47 6.46 Ser 2.80 0.66
108 Gly 2.80 3.18 Ser 22.20 14.12
109 Thr 13.09 10.35
110 Gly 2.90 1.59 Arg 18.86 10.46
111 Thr 0.60 3.50
111.1 Arg 0.80 6.60
111.2 Arg 6.82 3.76 Arg 15.66 12.11
112.1 Ser 8.79 10.51 Tyr 12.51 11.11 Ala 12.86 8.82
112 Leu 5.49 3.50 Gln 16.11 10.26
113 Tyr 13.59 16.24 Ala 10.07 7.11
114 Tyr 0.30 3.18
LCDR1 38 Asn 3.48 3.69
40
c His 2.69 1.85
LCDR2 52 Leu 0.00 6.60
55
c Tyr 4.82 12.01
56
c Ser 7.06 2.11
LCDR3 107 Arg 15.92 4.88 His 15.55 5.00
108 Tyr 9.17 5.53
114 Tyr 7.06 3.69
116 Trp 0.11 15.39
aPercentage contribution to interactions shown only for residues identified as important for recognition by site mapping.
bResults shown for HCDR3 conformer selected by dynamic site mapping.
cBy definition, these positions occur in CDR-adjacent framework regions.
doi:10.1371/journal.pone.0035457.t006
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predictions in GOLD for four of the validation cases. However,
increasing both the number of residues as well as the flexibility of
the carbohydrate (i.e., including one or more a(2R8) linkages)
generally results in reduced accuracy. This result is not surprising,
as these factors are known to affect the accuracy of molecular
docking [49]. Furthermore, the carbohydrates in the validation
cases contain multiple carboxylate groups, therefore, it is possible
that the incorrect carboxylate group could be paired against a
specific arginine residue, particularly if the rest of molecule can be
accommodated in the binding site and favorably scored. This is
not an issue for the majority of the test cases (Table 2), which
feature only one carboxylate group. Since only a limited number
of antibodies are available for use as validation cases, the effect of
binding site topography on docking accuracy could not be
effectively studied, as it had been previously [34,45]. However,
the case of 3HZV, which contains a large, highly flexible
carbohydrate, suggests that subtle changes in binding site
topography have a dramatic impact on docking accuracy.
In our previous site mapping studies, identical cutoffs of
hydrogen bonding and van der Waals interactions were used to
select residues involved in ligand recognition [32,34,36]. However,
the use of identical cutoffs for both of these interaction types does
not result in an optimal model for gangliosides. A significant bias
towards hydrogen bonding interactions is needed to accurately
represent antibody recognition of acidic sugars. Furthermore,
consideration of van der Waals interactions resulted in only a slight
improvement in the overall accuracy of the site mapping
procedure. This suggests that hydrogen bonding interactions are
significantly more important for antibody recognition of acidic
sugars than van der Waals interactions. Systems previously studied
via site mapping [32,34,36] may benefit from this ‘‘mixed’’
treatment of hydrogen bonding and van der Waals interactions.
The dynamic mapping study of chP3 demonstrates that the site
mapping technique has applications not just in identifying
antibody residues important for ligand interactions, but also in
identifying the likely bioactive conformation of CDR loops,
particularly HCDR3, which is often crucial for antigen recognition
and for which no canonical structures exist [54,55]. Importantly,
the selected protein conformer did not correspond with the lowest
energy state identified, suggesting that, at least in the case of chP3,
conformational change upon antigen binding may be important in
Figure 5. Site maps of anti-ganglioside antibodies. Hydrogen bonding and van der Waals site maps of R24 (A and B), ME36.1 (C and D) and
14F7 (E and F). Residues contributing to the likely ganglioside-binding motif are labeled on the hydrogen bonding site maps.
doi:10.1371/journal.pone.0035457.g005
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mechanisms in antigen binding has been explored earlier by a
number of groups [56,57,58,59,60]. The dynamic mapping study
highlights the potential usefulness of the site mapping technique in
the homology modeling of antibodies and in the structural
elucidation of conformational change upon antigen binding.
Although the four anti-ganglioside antibodies studied have quite
distinct binding site topographies and varying specificities
(Table 2), enough similarities in residue utilization across the set
could be identified to propose a potential ganglioside-binding
motif. This suggests the possibility of structural convergence in the
immune response towards a given antigen class. Structural
convergence has been reported earlier for anti-Lewis Y antibodies
[61]. It is likely that anti-ganglioside antibodies specifically
recognize terminal sialic acid residues, since these are the most
accessible, and thus, antibodies may consistently contain a
particular sialic acid-binding motif. Structural analysis of addi-
tional anti-ganglioside antibodies is required in order to evaluate
this hypothesis. The currently identified motif provides a potential
framework for optimizing existing anti-ganglioside antibodies.
In comparing ganglioside and peptide recognition, we were able
to determine that peptides known to act as immunological mimics
of gangliosides could also act at least as partial structural mimics of
the gangliosides. Therefore, it may be possible to design peptides
which are capable of inducing an anti-ganglioside immune
response using the antibody site maps generated in this study.
Such a ‘‘design by mapping’’ procedure was proposed in our
earlier work in investigating peptide mimicry of aGal-terminating
carbohydrates [36]. Our results for docking anti-idiotypic
antibodies to anti-Neu5Gc-GM3 antibodies indicate that anti-
idiotypic antibodies do not act as structural mimics of gangliosides.
This is most likely due to protein-protein recognition involving a
more extensive interaction network compared with protein-
carbohydrate association.
While the site mapping technique solely evaluates ligand
recognition from the protein’s ‘‘point-of-view’’, it can be combined
with ligand-based mapping techniques to provide the complete
picture of ligand-protein recognition [62]. Thus, this study not
only suggested how gangliosides and their mimics are recognized
by antibodies, but also raised several important new lines of
inquiry relevant to future development of our mapping techniques.
Studies are currently underway to answer these new questions,
which will contribute to the robustness of the mapping techniques
in probing carbohydrate-antibody recognition and to better
understanding such recognition.
To summarize our findings, the anti-ganglioside antibodies
studied here largely utilize a motif of four residues to recognize
gangliosides (Ser, polar, aromatic, Arg). These residues are
arranged within the binding site of each antibody studied here
in a relatively similar fashion. Peptides which bind to anti-
ganglioside antibodies and elicit anti-ganglioside immune respons-
es were found to act as structural mimics of the gangliosides,
providing a case where structural mimicry translates into
immunological mimicry. Our findings provide structural details
invaluable for the future development of ganglioside-targeting
cancer vaccines or optimizing therapeutic antibodies, as well as
demonstrating the potential role of the site mapping technique in
structure-based vaccine design.
Figure 6. Peptide mimicry of GD3 binding to R24. A. Hydrogen bonding site map describing peptide (RHAYRSMAEWGFLYS) recognition by
R24. B. van der Waals interaction site map describing peptide recognition by R24. Site maps generated and rendered using PyMOL [64]. C.
Comparison of hydrogen bonding site maps describing GD3 and peptide recognition. D. Comparison of van der Waals site maps describing GD3 and
peptide recognition. In Figures 6C and 6D, open points indicate residues which deviate significantly from the line representing equivalence of
carbohydrate and peptide interactions (i.e., |d|.3.00). The open point not labeled on Figure 6C corresponds with Tyr114H.
doi:10.1371/journal.pone.0035457.g006
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